CELLforCURE by SEQENS, a leading Contract Development and Manufacturing Organization (CDMO)  specialized in Advanced Therapy Medicinal Products (ATMPs), is pleased to announce a strategic  partnership with Galapagos NV (Euronext & NASDAQ: GLPG) to support the decentralized  manufacturing for clinical development of Galapagos’ CD19 CAR T-cell therapy candidate, GLPG5101,  investigated in multiple relapsed/refractory non-Hodgkin lymphoma (NHL) indications. The  collaboration could be broadened to include the manufacturing of additional product candidates in  Galapagos’ portfolio. 

CELLforCURE by SEQENS’ state-of-the-art commercial cell therapy manufacturing facility in Les Ulis,  France, will play a key role in supporting Galapagos’ upcoming trials in Paris and the broader France area. 

Galapagos’ Cell Therapy Manufacturing Platform 

Galapagos’ innovative decentralized manufacturing platform for cell therapies is designed to be  deployed close to cancer treatment centers. By bringing the manufacturing process closer to patients,  Galapagos’ platform is designed to deliver fresh, fit, stem-like early memory cell therapy with a median  vein-to-vein time of seven days, thereby avoiding cryopreservation and eliminating the need for  cytotoxic bridging therapy. 

Strategic Choice of CELLforCURE by SEQENS 

The selection of CELLforCURE by SEQENS as a manufacturing partner is based on CELLforCURE’s proven  expertise in GMP-compliant commercial-scale cell therapy production. As a recognized player in France,  CELLforCURE by SEQENS has worked closely with French hospitals for over five years, actively  contributing to the establishment of the first local CAR-T manufacturing pathways in the European  Union. 

With its strategic location in Les Ulis, near major treatment centers in Paris and the broader France  area, CELLforCURE by SEQENS enables Galapagos to realize its ambition of a decentralized  manufacturing network bringing treatments closer to patients for faster and more efficient access to  care. 

Harnessing Innovation and Experience to Deliver Cell Therapies 

“We are proud and honored to support Galapagos at this pivotal stage of development for GLPG5101”  said Marc-Olivier Mignon, President of CELLforCURE by SEQENS. “Our expertise in advanced therapy  manufacturing at clinical and commercial stage will support the integration of disruptive cutting-edge technologies as well as the release of a fresh, early-memory-enriched cell therapy.”